Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Medical Genetics · Early-Onset Dystonia and Hereditary Spastic Paraplegia

Decoding the Genetic Report and Subtypes

At a Glance

To understand a child’s early-onset dystonia or hereditary spastic paraplegia, focus on the gene, exact variant, inheritance pattern, and classification. A negative or uncertain result does not rule out a genetic condition and may warrant specialist review or additional testing.

Receiving a genetic report can feel like being handed a map written in a foreign language. While the technical terms are complex, this document is the most important tool your care team has for understanding your child’s specific condition. It moves the conversation from “what is happening” to “why it is happening” [1].

Families should discuss pre-test and post-test counseling, privacy choices, and incidental findings with a genetics professional before testing, and results should always be interpreted with their help.

Choosing the Right Test

Not all genetic tests are the same, and they are selected according to the phenotype and prior results.

  • Targeted Panels: These look at a pre-set list of genes known to cause movement disorders or spasticity. They are efficient if your child’s symptoms strongly match a specific category [2].
  • Whole Exome Sequencing (WES): This looks at the exome, the 1-2% of our DNA that contains the instructions for making proteins, where most known disease-causing variants occur [3][4].
  • Whole Genome Sequencing (WGS): This looks at a larger portion of the DNA. It can find some variants that WES might miss, such as changes in the areas between genes [5][6].
  • Limitations: Note that WES and WGS can miss or inadequately assess repeat expansions, structural and copy-number changes, and mitochondrial variants. A negative result may simply mean a different test is needed.

Common Subtypes and What They Mean

“Hereditary Spastic Paraplegia” and “Early-Onset Dystonia” are umbrella terms. The specific “SPG” number or gene name tells you which subtype your child has.

Leading Spastic Paraplegia Subtypes

  • SPG4 (SPAST gene): The most common form of HSP. It typically causes progressive leg stiffness and weakness. While it can vary greatly in severity, it is often a “pure” form, meaning other neurological systems are usually not involved [7][8].
  • SPG11 (KIAA1840 gene): This is often a “complex” form. In addition to walking difficulties, children may experience cognitive challenges, speech changes, or a thin corpus callosum (the bridge between the brain’s two halves) on an MRI [9][10].
  • AP-4 Deficiency (SPG47, 50, 51, 52): This group of subtypes often begins in infancy with low muscle tone (hypotonia) followed by progressive stiffness. It is frequently associated with developmental delays and epilepsy [11][12].

Leading Dystonia Subtypes

  • KMT2B-Related Dystonia: This often starts in the feet or legs in early childhood and can sometimes spread. It is often associated with specific facial features and sometimes minor developmental delays [13].
  • GCH1 (Dopa-Responsive Dystonia): A critical subtype to identify because it can be responsive to a medication called levodopa. It may look like “stiff” walking that worsens as the day goes on [14][15].
  • FA2H-Related (SPG35): This rare subtype involves a spectrum of symptoms including spasticity, dystonia, and sometimes changes in vision or coordination [16].

Your Genetic Report Checklist

A complete genetic report should be detailed enough for any specialist in the world to understand. Ensure your copy includes these four key pieces of data:

  1. Gene Name: The specific gene where the change was found (e.g., SPAST, KIAA1840).
  2. Variant Description: The exact change in the DNA (e.g., c.1522C>T). This is like a GPS coordinate for the genetic variant [17].
  3. Zygosity/Inheritance: Whether the child has one copy (heterozygous) or two copies (homozygous/compound heterozygous) of the variant, and whether it was inherited or happened for the first time in the child (de novo) [18].
  4. Pathogenicity: Laboratories use a five-tier evidence-based classification system. The most definitive categories are Pathogenic or Likely Pathogenic [19][20]. Note that even a pathogenic variant may not fully explain the child’s phenotype without considering clinical fit.

If the Test is “Negative” or “Inconclusive”

A negative genetic test does not mean your child does not have a genetic condition; it only means the current test did not find it [5].

  • Variants of Uncertain Significance (VUS): This means a change was found, but the lab doesn’t have enough data yet to know if it’s harmful. A VUS should not guide medical management. Testing the biological parents can provide evidence but does not automatically upgrade or downgrade a VUS [21][22].
  • The Power of Re-analysis: Genetic science moves fast. If a test was negative, asking the lab to re-analyze the existing raw data later may be useful because new genes are discovered every year (though it is not guaranteed and not always performed on request) [4][23].
  • Missing Pieces: If standard sequencing is negative, your doctor may recommend broader diagnostic workups, including repeat-expansion testing or other specialized methods [24][6].

Common questions in this guide

What information should I look for in my child’s genetic report?
Look for the gene name, the exact DNA variant, whether the change is in one or both copies of the gene, how it was inherited, and the laboratory’s classification. A genetics professional should interpret these details together with your child’s symptoms and examination.
Does a negative genetic test mean my child does not have a genetic condition?
No. A negative result means that the test did not identify a cause; some tests miss repeat expansions, structural or copy-number changes, mitochondrial variants, or changes in genes not yet recognized. A specialist may recommend a different test or later reanalysis.
What does a variant of uncertain significance mean?
A variant of uncertain significance, or VUS, is a DNA change whose health effect is not known yet. It should not be used by itself to change medical management; testing biological parents may add evidence, but it does not automatically prove whether the variant is harmful.
What is the difference between whole exome and whole genome sequencing?
Whole exome sequencing examines the protein-coding portion of DNA, while whole genome sequencing examines a broader portion, including some regions between genes. Neither test detects every type of genetic change, so a negative result may require specialized testing.
Can identifying a genetic subtype change my child’s treatment?
Yes, identifying a subtype can reveal treatments or monitoring needs that are especially relevant to that condition. For example, some children with GCH1-related dopa-responsive dystonia may improve with levodopa, which should be considered and prescribed by the child’s clinician.
What do SPG4, SPG11, and AP-4 deficiency tell us?
These names identify different genetic forms of hereditary spastic paraplegia. SPG4 often mainly affects leg stiffness and weakness, SPG11 may also involve cognition, speech, or a thin corpus callosum—the bridge between the brain’s two halves—and AP-4 deficiency often begins with low muscle tone followed by stiffness and may include developmental delay or epilepsy.
When can a genetic test be reanalyzed?
Reanalysis may be useful after a negative or inconclusive result because new disease genes and evidence are discovered over time. Ask the genetics team when the laboratory can review the stored data; reanalysis is not guaranteed and may not be done automatically.

Get notified when new evidence is published on dystonia, early-onset, and/or spastic paraplegia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (24)
  1. 1

    The genetic landscape of childhood-onset dystonia in a nationwide Turkish cohort: Clinical spectrum, molecular diagnostics, and therapeutic implications.

    Yilmaz S, Serdaroglu E, Simsek E, et al.

    European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society 2026; (62()):51-60 doi:10.1016/j.ejpn.2026.06.003.

    PMID: 42308683
  2. 2

    A Clinical and Integrated Genetic Study of Isolated and Combined Dystonia in Taiwan.

    Wu MC, Chang YY, Lan MY, et al.

    The Journal of molecular diagnostics : JMD 2022; (24(3)):262-273 doi:10.1016/j.jmoldx.2021.12.003.

    PMID: 35041927
  3. 3

    Childhood-onset hereditary spastic paraplegia: at the crossroads between neurodevelopment and neurodegeneration.

    Espasandin-Hueter N, Salazar-Villacorta A, Escudero JM, et al.

    European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society 2026; (65()):50-65 doi:10.1016/j.ejpn.2026.10.002.

    PMID: 42976539
  4. 4

    Clinical diagnostic exome sequencing in dystonia: Genetic testing challenges for complex conditions.

    Powis Z, Towne MC, Hagman KDF, et al.

    Clinical genetics 2020; (97(2)):305-311 doi:10.1111/cge.13657.

    PMID: 31628766
  5. 5

    Diagnostic yield of genome sequencing in children with progressive movement disorders.

    Schierbaum L, Gonzalez Saez-Diez E, Tam A, et al.

    Brain : a journal of neurology 2026; (149(10)):3404-3413 doi:10.1093/brain/awag050.

    PMID: 41640354
  6. 6

    Combined genomics and proteomics unveils elusive variants and vast aetiologic heterogeneity in dystonia.

    Zech M, Dzinovic I, Skorvanek M, et al.

    Brain : a journal of neurology 2025; (148(8)):2827-2846 doi:10.1093/brain/awaf059.

    PMID: 39937650
  7. 7

    Spastic paraplegia type 4: A novel SPAST splice site donor mutation and expansion of the phenotype variability.

    Kawarai T, Montecchiani C, Miyamoto R, et al.

    Journal of the neurological sciences 2017; (380()):92-97 doi:10.1016/j.jns.2017.07.011.

    PMID: 28870597
  8. 8

    Genotype-structure-phenotype correlations define divergent natural history in early-onset spastic paraplegia type 4.

    Alecu JE, Schierbaum LM, Tam A, et al.

    Brain : a journal of neurology 2026; doi:10.1093/brain/awag150.

    PMID: 42083457
  9. 9

    Hereditary spastic paraplegia type 11: Clinicogenetic lessons from 339 patients.

    Du J

    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2021; (85()):67-71 doi:10.1016/j.jocn.2020.11.036.

    PMID: 33581793
  10. 10

    Motor neuron degeneration in spastic paraplegia 11 mimics amyotrophic lateral sclerosis lesions.

    Denora PS, Smets K, Zolfanelli F, et al.

    Brain : a journal of neurology 2016; (139(Pt 6)):1723-34 doi:10.1093/brain/aww061.

    PMID: 27016404
  11. 11

    Defining the clinical, molecular and imaging spectrum of adaptor protein complex 4-associated hereditary spastic paraplegia.

    Ebrahimi-Fakhari D, Teinert J, Behne R, et al.

    Brain : a journal of neurology 2020; (143(10)):2929-2944 doi:10.1093/brain/awz307.

    PMID: 32979048
  12. 12

    Systematic Analysis of Brain MRI Findings in Adaptor Protein Complex 4-Associated Hereditary Spastic Paraplegia.

    Ebrahimi-Fakhari D, Alecu JE, Ziegler M, et al.

    Neurology 2021; (97(19)):e1942-e1954 doi:10.1212/WNL.0000000000012836.

    PMID: 34544818
  13. 13

    Scoring Algorithm-Based Genomic Testing in Dystonia: A Prospective Validation Study.

    Zech M, Jech R, Boesch S, et al.

    Movement disorders : official journal of the Movement Disorder Society 2021; (36(8)):1959-1964 doi:10.1002/mds.28614.

    PMID: 33949708
  14. 14

    Autosomal dominant GCH1 mutations causing spastic paraplegia at disease onset.

    Wassenberg T, Schouten MI, Helmich RC, et al.

    Parkinsonism & related disorders 2020; (74()):12-15 doi:10.1016/j.parkreldis.2020.03.019.

    PMID: 32278297
  15. 15

    Dopa-responsive dystonia in Chinese patients: Including a novel heterozygous mutation in the GCH1 gene with an intermediate phenotype and one case of prenatal diagnosis.

    Zhang W, Zhou Z, Li X, et al.

    Neuroscience letters 2017; (644()):48-54 doi:10.1016/j.neulet.2017.01.019.

    PMID: 28087438
  16. 16

    FAHN/SPG35: a narrow phenotypic spectrum across disease classifications.

    Rattay TW, Lindig T, Baets J, et al.

    Brain : a journal of neurology 2019; (142(6)):1561-1572 doi:10.1093/brain/awz102.

    PMID: 31135052
  17. 17

    Familial White-Sutton Syndrome Caused by a Pathogenic POGZ p.Arg508* Variant: Intrafamilial Variability from Childhood to Adulthood.

    Chetta M, Lattarulo S, Stasi M, et al.

    Genes 2026; (17(6)) doi:10.3390/genes17060722.

    PMID: 42353881
  18. 18

    Molecular Diagnostic Yield and Genotype-Phenotype Spectrum of Inherited Eye Diseases in a Tertiary Health Center in Türkiye.

    Çevik MÖ

    Beyoglu eye journal 2026; (11(3)):266-271 doi:10.14744/bej.2026.75391.

    PMID: 42898535
  19. 19

    Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

    Richards S, Aziz N, Bale S, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2015; (17(5)):405-24 doi:10.1038/gim.2015.30.

    PMID: 25741868
  20. 20

    Clinical Interpretation of Sequence Variants.

    Zhang J, Yao Y, He H, Shen J

    Current protocols in human genetics 2020; (106(1)):e98 doi:10.1002/cphg.98.

    PMID: 32176464
  21. 21

    Comparison of The Results of Sponsored Genetic Testing Panels for Inherited Retinal Diseases.

    Bao YK, Situ BA, Runner M, et al.

    Journal of clinical medicine 2024; (13(11)) doi:10.3390/jcm13113118.

    PMID: 38892829
  22. 22

    [A consensus on the standardization of the next generation sequencing process for the diagnosis of genetic diseases (4) - Report interpretation and genetic counseling].

    Huang H, Shen Y, Gu W, et al.

    Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics 2020; (37(3)):352-357 doi:10.3760/cma.j.issn.1003-9406.2020.03.022.

    PMID: 32128757
  23. 23

    A Practical Guide to Genetic Testing for Kidney Disorders of Unknown Etiology.

    Aron AW, Dahl NK, Besse W

    Kidney360 2022; (3(9)):1640-1651 doi:10.34067/KID.0007552021.

    PMID: 36245662
  24. 24

    High Genetic Diagnostic Yield for Patients with Rare Movement Disorders at a Single-Center Neurogenetics Clinic.

    Penn D, Amir Y, David GB, et al.

    Movement disorders clinical practice 2025; (12(11)):1811-1820 doi:10.1002/mdc3.70145.

    PMID: 40470849

This page is for informational purposes only and does not constitute medical advice. A genetics professional or neurologist should interpret your child’s report and advise care.

Guide contents dystonia, early-onset, and/or spastic paraplegia
Research & Literature
02 What It Is and What It Isn't 04 Symptoms, Variability, and Progression